Privium Fund Management B.V. Sells 20,829 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Privium Fund Management B.V. lowered its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 17.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 97,154 shares of the biopharmaceutical company’s stock after selling 20,829 shares during the period. Intra-Cellular Therapies comprises approximately 1.8% of Privium Fund Management B.V.’s holdings, making the stock its 13th largest holding. Privium Fund Management B.V.’s holdings in Intra-Cellular Therapies were worth $8,114,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Raymond James Financial Inc. bought a new position in shares of Intra-Cellular Therapies during the fourth quarter valued at approximately $76,451,000. TimesSquare Capital Management LLC lifted its holdings in Intra-Cellular Therapies by 91.8% during the fourth quarter. TimesSquare Capital Management LLC now owns 840,269 shares of the biopharmaceutical company’s stock worth $70,179,000 after buying an additional 402,186 shares during the period. Eagle Asset Management Inc. boosted its position in Intra-Cellular Therapies by 130.5% during the 3rd quarter. Eagle Asset Management Inc. now owns 624,759 shares of the biopharmaceutical company’s stock valued at $45,714,000 after acquiring an additional 353,723 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of Intra-Cellular Therapies by 9.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,753,286 shares of the biopharmaceutical company’s stock valued at $129,463,000 after acquiring an additional 155,655 shares during the period. Finally, Wasatch Advisors LP raised its position in shares of Intra-Cellular Therapies by 3.5% in the 3rd quarter. Wasatch Advisors LP now owns 3,848,588 shares of the biopharmaceutical company’s stock worth $281,601,000 after acquiring an additional 130,351 shares in the last quarter. 92.33% of the stock is currently owned by institutional investors.

Intra-Cellular Therapies Price Performance

Shares of ITCI opened at $131.45 on Wednesday. The company’s fifty day moving average price is $125.91 and its 200-day moving average price is $96.52. Intra-Cellular Therapies, Inc. has a 1-year low of $63.87 and a 1-year high of $131.48. The firm has a market capitalization of $13.98 billion, a PE ratio of -151.09 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The firm had revenue of $199.22 million for the quarter, compared to analysts’ expectations of $205.08 million. As a group, research analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on ITCI shares. Mizuho downgraded Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $140.00 to $132.00 in a research report on Monday, February 24th. Royal Bank of Canada restated a “sector perform” rating and issued a $132.00 price target (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Piper Sandler reissued a “neutral” rating and set a $132.00 target price (up previously from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Finally, StockNews.com initiated coverage on shares of Intra-Cellular Therapies in a report on Wednesday, March 12th. They issued a “hold” rating on the stock. Ten equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Intra-Cellular Therapies has a consensus rating of “Hold” and a consensus price target of $106.08.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.